Bayer mulls challenge to India cancer drug ruling

Updated - November 16, 2021 11:21 pm IST

Published - March 13, 2012 11:50 pm IST

Bayer AG said, on Tuesday, it was mulling ways to challenge a ground-breaking Indian ruling allowing a local firm to produce a vastly cheaper copy of a cancer drug made by the German pharmaceutical giant.

The ruling on Monday by India's Controller-General of Patents marked the first time a so-called ‘compulsory licence' for production of a patented drug has been granted in India, known as a global generics drug powerhouse.

Evaluating options

“We will evaluate our (legal) options to further defend our intellectual property rights in India,'' Bayer spokesman Aloke Pradhan told AFP, saying the company was “disappointed by the decision.''

Under the ruling, closely watched by global drugmakers, Bayer must give a licence for cancer drug Nexavar to Indian company Natco Pharma.

Royalty

Natco will pay Bayer a 6 per cent royalty on net sales of the drug and sell the medicine for Rs.8,800 ($175) a month. That sum represents a 97 per cent reduction on the Rs.2.80 lakh that Bayer charges in India for a monthly dose of the drug, which is used to extend the lives of patients suffering from advanced kidney and liver cancers.

Indian patent controller P. H. Kurian granted the right to Natco to produce the drug after concluding Bayer had priced the drug ‘exorbitantly,' making it ‘out of reach' of most Indian patients.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.